European Union - English - EMA (European Medicines Agency)

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - thalidomide 100mg - capsule - 100 mg - active: thalidomide 100mg excipient: gelatin magnesium stearate pregelatinised maize starch - · thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years or older, or ineligible for high dose chemotherapy. · thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. ·thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - thalidomide 150mg - capsule - 150 mg - active: thalidomide 150mg excipient: gelatin magnesium stearate pregelatinised maize starch - · thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years or older, or ineligible for high dose chemotherapy. · thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. ·thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - thalidomide 200mg - capsule - 200 mg - active: thalidomide 200mg excipient: gelatin magnesium stearate pregelatinised maize starch - · thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years or older, or ineligible for high dose chemotherapy. · thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. ·thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - thalidomide 50mg - capsule - 50 mg - active: thalidomide 50mg excipient: gelatin magnesium stearate pregelatinised maize starch - · thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years or older, or ineligible for high dose chemotherapy. · thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. ·thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 10mg;   - capsule - 10 mg - active: lenalidomide 10mg   excipient: capsugel yellow 4035 capsule blue-green 6579 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 15mg;   - capsule - 15 mg - active: lenalidomide 15mg   excipient: capsule blue 3628 capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 25mg;   - capsule - 25 mg - active: lenalidomide 25mg   excipient: capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 5mg;   - capsule - 5 mg - active: lenalidomide 5mg   excipient: capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 2.5mg;   - capsule - 2.5 mg - active: lenalidomide 2.5mg   excipient: capsule blue-green 6579 capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation